Research programme: anti-inflammatory and skin disorder therapeutics - LEO Pharma/Model Medicines
Latest Information Update: 28 Aug 2024
At a glance
- Originator LEO Pharma; Repurpose AI
- Developer LEO Pharma; Model Medicines
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Anti-neutrophil cytoplasmic antibody-associated vasculitis
- No development reported Inflammation; Skin disorders
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for research development in Inflammation in Denmark
- 28 Aug 2024 No recent reports of development identified for research development in Inflammation in USA
- 09 Jan 2023 Early research in Anti-neutrophil cytoplasmic antibody-associated vasculitis in Denmark (unspecified route) prior to January 2023 (Model Medicines website, January 2023)